Ibogaine is classified as a stupéfiant (narcotic) under French domestic law, making its possession, sale, and use illegal without specific governmental authorization. Last verified: April 2026.

Current Legal Status

France prohibits ibogaine under the Code de la santé publique (Public Health Code), specifically through scheduling decisions made by the Agence nationale de sécurité du médicament et des produits de santé (ANSM), France's national medicines regulator. Ibogaine is listed as a stupéfiant — the most restrictive category under French drug law — which applies controls equivalent to those placed on heroin and cocaine under domestic regulation.

Important clarification: France's classification of ibogaine as a narcotic is based entirely on French national law and ANSM scheduling decisions. Ibogaine is not scheduled under the 1961 UN Single Convention on Narcotic Drugs and remains internationally unscheduled at the UN level. France acted unilaterally through domestic legislation, independent of any UN treaty obligation.

Under the stupéfiant classification:

  • Possession is a criminal offense, regardless of quantity or stated intent.
  • Sale, supply, or trafficking carries severe criminal penalties, including substantial prison sentences.
  • Manufacturing or extraction of ibogaine or ibogaine-containing preparations is prohibited.
  • Import and export require specific ANSM authorization, which is not available for personal use or clinical treatment outside approved research frameworks.

There are currently no recognized religious exemptions under French law for ibogaine use, unlike the legal carve-outs that exist in some jurisdictions for substances such as ayahuasca used in specific ceremonial contexts. France's laïcité (secularism) framework does not extend recognized legal protections for psychedelic sacramental use.

Research exemptions exist in principle: institutions may apply to the ANSM for authorization to conduct clinical research involving controlled substances, but as of April 2026, no publicly registered ibogaine clinical trials are actively recruiting in France. Any such research would require extensive regulatory approval before commencing.

Treatment Centers

There are no legal ibogaine treatment centers operating in France. Because ibogaine is scheduled as a stupéfiant with no approved therapeutic indication in France, no clinic or practitioner may legally administer ibogaine to patients on French soil.

French nationals and residents who seek ibogaine-assisted treatment typically travel abroad to jurisdictions where treatment clinics operate legally. Countries with legal or formally tolerated ibogaine treatment programs include Mexico, Portugal, Gabon, and South Africa, among others.

For a full directory of vetted international clinics, see our ibogaine clinic directory.

How People Access Ibogaine in France

Despite its stupéfiant classification, some individuals in France do attempt to access ibogaine. This page documents known patterns factually — none of the following constitute recommendations or legal advice.

  • Medical tourism: The most common route for French residents seeking ibogaine treatment is traveling to licensed clinics in countries such as Mexico, Portugal, the Netherlands, or South Africa, where treatment is legal or operates in a regulated framework. Such travel is legal in itself, though returning to France with ibogaine in any form would constitute a criminal offense.
  • Underground administration: Illegal ibogaine sessions do occur in France, typically administered by individuals without medical training or in informal settings. These carry serious legal risk alongside significant health risks due to the absence of medical supervision, cardiac monitoring, and quality-controlled sourcing.
  • Online procurement: Some individuals attempt to purchase ibogaine hydrochloride, total alkaloid extracts, or Tabernanthe iboga root bark via international online vendors. Importing such substances into France violates customs and narcotics law and carries criminal liability.
  • Harm reduction networks: A small number of harm reduction organizations in France provide information about ibogaine risks, though they cannot legally facilitate access or administration.

Health warning: Ibogaine carries serious cardiovascular risks, including potentially fatal cardiac arrhythmias. Administration outside a medically supervised environment with cardiac monitoring equipment and emergency protocols is dangerous. Underground access in France eliminates these protections entirely.

Recent Legal Developments

France has not moved to reschedule or decriminalize ibogaine in recent years, and no legislative proposals to do so are currently advancing in the French Parliament as of April 2026.

The broader context of international ibogaine policy has shifted considerably, with the United States completing a Phase 2 clinical trial landscape and Australia's Therapeutic Goods Administration (TGA) approving MDMA and psilocybin for specific therapeutic uses. These developments have generated academic and media discussion in France, but have not translated into regulatory action by the ANSM or policy proposals from the Ministère de la Santé.

France's general drug policy has remained comparatively restrictive by Western European standards. While neighboring countries such as Portugal decriminalized personal drug possession in 2001, and the Netherlands operates a formal tolerance (gedoogbeleid) policy for cannabis, France has maintained criminal penalties for personal possession of all controlled substances, including stupéfiants.

The ANSM continues to review its scheduling lists periodically, but no public consultation or proposal to reclassify ibogaine has been announced. Researchers and advocates monitoring French regulatory activity should consult the ANSM official website for the latest scheduling updates.

International advocacy organizations, including MAPS (Multidisciplinary Association for Psychedelic Studies) and the Global Ibogaine Therapist Alliance (GITA), have not reported active lobbying campaigns targeting French regulators as of April 2026.

Risks of Seeking Treatment in France

Seeking or facilitating ibogaine treatment within France carries overlapping legal and health risks that are substantially greater than in jurisdictions with legal frameworks.

Legal Risks

  • Criminal prosecution: Possession of ibogaine as a stupéfiant carries criminal liability. Prosecutors have discretion over whether to pursue charges for personal use versus supply, but the legal exposure is real and meaningful.
  • Customs interception: Attempting to import ibogaine or iboga root bark through French customs — including by post or personal luggage — constitutes drug importation and may result in prosecution.
  • Third-party liability: Individuals who facilitate or assist in administering ibogaine to another person in France face potential prosecution for drug supply and, if harm results, additional criminal exposure.

Medical and Safety Risks

  • No quality control: Ibogaine obtained through illegal channels has no verified purity, concentration, or composition. Adulteration or mislabeling poses severe overdose risk.
  • No cardiac monitoring: Ibogaine prolongs the QT interval and can cause life-threatening ventricular arrhythmias. Legal clinical settings require baseline ECG screening, continuous cardiac monitoring, and emergency response capability. Underground settings cannot reliably provide these.
  • No pre-screening: Legal clinics screen candidates for contraindicated conditions including heart disease, liver dysfunction, and dangerous medication interactions (particularly with medications affecting cardiac rhythm or serotonin). Underground settings typically cannot conduct equivalent screening.
  • No follow-up care: Integration support and medical follow-up after an ibogaine experience contribute to both safety and therapeutic outcomes. These are absent in informal settings.

Frequently Asked Questions

No. Ibogaine is classified as a stupéfiant (narcotic) under the French Code de la santé publique, based on scheduling decisions by the ANSM. This makes possession, use, sale, and importation illegal without specific governmental authorization, which is not available for personal use or general clinical treatment. There are no religious exemptions or decriminalization provisions that apply to ibogaine in France.
No. This is a common misconception. Ibogaine is not scheduled under the 1961 UN Single Convention on Narcotic Drugs, nor under the 1971 UN Convention on Psychotropic Substances. It remains internationally unscheduled at the UN level. France's classification of ibogaine as a stupéfiant is based entirely on French national law and autonomous ANSM scheduling decisions, not on any international treaty obligation.
Traveling from France to a country where ibogaine treatment is legal — such as Mexico, Portugal, or South Africa — is not itself prohibited under French law. French law does not generally criminalize activities that occur legally in other jurisdictions when conducted there. However, returning to France with any ibogaine or iboga-derived material in your possession would constitute illegal importation of a stupéfiant and could result in criminal charges. Consult a licensed attorney for advice specific to your situation.
As of April 2026, no publicly registered ibogaine clinical trials are actively recruiting participants in France. Conducting research involving stupéfiants in France requires specific ANSM authorization. While such authorizations are theoretically available to qualifying research institutions, none have led to active ibogaine trials in the public registry. The ANSM website and the EU Clinical Trials Register are the appropriate sources to check for any future developments.
Under the Code de la santé publique, personal possession of a stupéfiant is a criminal offense punishable by up to one year of imprisonment and fines. In practice, prosecutorial discretion is exercised and first-time personal-use offenders may be directed toward treatment or warnings rather than prosecution — but this is not guaranteed, and the legal exposure remains. Trafficking, supply, or importation carries significantly heavier penalties, including multi-year prison sentences. These are general parameters under French law; actual outcomes vary by case. Consult a licensed French attorney for case-specific guidance.
There is no active legislative proposal or ANSM consultation underway to reclassify or decriminalize ibogaine in France as of April 2026. France's overall drug policy framework has remained comparatively restrictive by Western European standards, and the political climate has not generated significant momentum toward psychedelic rescheduling equivalent to movements seen in the United States or Australia. Monitoring the ANSM and the Journal officiel de la République française is the most reliable way to track any future regulatory changes.

Informational only. Not legal advice. Laws change. Verify with a licensed attorney before making any decisions.